Opioid Use Disorders in Sub-Saharan Africa
Country-level opioid use disorders mortality data for Sub-Saharan Africa. Age-standardized death rates per 100,000 population from the IHME Global Burden of Disease Study.
| # | Country | Rate |
|---|
This page presents opioid use disorders mortality data for countries in Sub-Saharan Africa, using age-standardized death rates per 100,000 population from the Institute for Health Metrics and Evaluation (IHME). Regional analysis reveals significant variation in disease burden between countries, reflecting differences in healthcare infrastructure, socioeconomic conditions, environmental risk factors, and public health policy implementation across Sub-Saharan Africa.
Opioid use disorders involve compulsive use of opioid substances — prescription analgesics such as oxycodone and fentanyl, as well as illicit heroin and increasingly potent synthetic analogues — despite harmful consequences. Death occurs primarily through respiratory depression: opioids bind mu-receptors in the brainstem's respiratory centres, suppressing the drive to breathe, leading to hypoxia, cardiac arrest, and death within minutes of overdose. The opioid crisis has devastated North America, where the United States alone recorded over 80,000 opioid-involved overdose deaths in 2022 — a roughly tenfold increase from 2000. The epidemic evolved in three waves: prescription opioid overprescribing in the late 1990s, a shift to heroin after 2010, and the emergence of illicitly manufactured fentanyl and its analogues after 2013. While North America bears the most visible burden, opioid-related mortality is rising in West Africa (tramadol), the Middle East, and parts of Europe. The social determinants are profound: deindustrialisation, economic despair, adverse childhood experiences, chronic pain mismanagement, and fractured social cohesion all feed the epidemic. Sub-Saharan Africa faces the world's most acute health challenges, with the youngest population of any region, the highest burden of infectious diseases, and health systems constrained by limited financing and workforce shortages. In Sub-Saharan Africa, opioid use disorders mortality is broadly in line with global averages, though the region's young demographic profile and high infectious disease burden shape the overall mortality landscape.
Opioid overdose deaths are preventable through naloxone distribution (the opioid antagonist reverses respiratory depression within minutes), medication-assisted treatment with methadone or buprenorphine, supervised consumption sites, prescription drug monitoring programmes, and evidence-based pain management guidelines that reduce unnecessary opioid prescribing. Harm reduction — including fentanyl test strips and safe supply programmes — addresses the reality that abstinence-only approaches fail many individuals with opioid use disorder.
The mortality estimates presented on this page are derived from the Global Burden of Disease (GBD) study, produced by the Institute for Health Metrics and Evaluation (IHME). The GBD synthesizes data from vital registration systems, verbal autopsies, cancer registries, and surveillance networks across more than 200 countries and territories. Death rates are expressed per 100,000 population and are age-standardized, which adjusts for differences in age structure between populations so that comparisons across countries and over time reflect genuine differences in mortality risk rather than demographic composition.
The dataset typically covers the period from 1990 to 2023, although availability varies by country and cause. When interpreting the figures for opioid use disorders in Sub-Saharan Africa, note that higher age-standardized rates indicate a greater mortality burden independent of whether a country's population is older or younger. Trends over time reveal whether public health interventions, economic development, and health system improvements have reduced or increased the toll of this condition in the region.
Disease-specific death rates measure the number of deaths directly attributed to opioid use disorders per 100,000 people, after accounting for age structure. These rates capture both the prevalence of the condition and the likelihood of a fatal outcome once affected. In Sub-Saharan Africa, variation across countries may reflect differences in disease prevalence, access to treatment, diagnostic capacity, and the presence of comorbidities. Examining trends alongside health expenditure and intervention coverage helps identify where policy action has been most effective.